8:00 am Registration & Welcome Coffee
8:50 am Chair’s Opening Remarks
Late-Breaking Data in ImmunoDerm: Novel Treatments & Approvals on the Horizon
9:00 am Late-Breaking Preclinical Data: Novel Anti-FasL mAb for Severe Dermatologic Conditions
Synopsis
- Discover a novel non-immunosuppressive approach targeting FasL in severe blistering conditions with significant mortality rates
- Explore preclinical efficacy data from validated disease models using proprietary humanised FasL mouse platform
- Understand unique clinical considerations for underserved ‘orphan’ dermatology indications
9:30 am Exploration of Phase 3 Data: Superior & Significant Efficacy Challenging Approved Therapies
Synopsis
- Measuring efficacy: Discover how therapeutic effects on biomarkers linked to core immuno-derm disease (eg. skin lesions, itch, sleep, and quality of life) are measured
- Documenting durability of response for multiple indications through inhibition of cytokine signalling
10:00 am Morning Speed-Networking Break
Synopsis
Our well-known networking format enabling all in the room to meet face to face before presentations resume. Find common ground with attendees through quick-fire conversations, before moving to the next table to meet another group.
A proven way to uncover the expertise of those attending, with vast experience specific to immunodermatological disease areas.
Disease Biology: Building Evidence to Validate Targetable Pathways & Inform Discovery Ventures
11:00 am Biological Crossovers: Uncovering Disease Targets with Biological Relevance Across Multiple-Disease
Synopsis
- Unmask shared pathologies to understand how shared biological mechanisms can accelerate drug discovery
- Map complex biological interactions and identify inflammatory pathways targeted for therapeutic intervention
11:30 am Cutaneous Immune Mapping: Enhance Treatment Efficacy Using Validated Biomarkers
Synopsis
- Understand unique properties of circulating CLA+ memory T cells as cellular biomarkers in AD
- Explore how circulating CLA+ T cells are involved in monitoring treatment response in AD
- Discover how CLA+ T cell allow functionally stratifying IL-13, IL-31, IL-9 and IL-22 responders in moderate-severe AD
12:00 pm Roundtable Discussion: Anti-Ox40 Therapeutic Landscape and Exploration of OX40 Targeting Industry Impact
Synopsis
Join an interactive discussion exploring OX40 as an emerging therapeutic target in dermatology. Following a brief overview of mechanism and current pipeline landscape, experts will engage in an open forum discussion addressing key questions and industry impacts.
- Where does OX40 targeting fit within current treatment paradigms, and what unique advantages might it offer over existing therapeutic approaches?
- What are the critical considerations for patient selection, stratification, and endpoint optimisation in clinical development?
- How can we maximise the potential of OX40 targeting through combination approaches and indication expansion?
12:30 pm Networking Lunch Break
Synopsis
Take this chance to meet the expert speakers, connect with your peers and explore our exhibition booths.
Understanding Disease: How Close is Industry to Delaying, Slowing or Reversing Disease Progression?
1:30 pm Curative vs. Chronic Treatment in Atopic Dermatitis: Navigating Commercial & Clinical Implications
Synopsis
- Review early safety profiles of therapeutic peptides in Atopic Dermatitis, examining their potential for targeted disease modification
- Compare emerging pathways targeting disease modification against established symptomatic treatments – evaluating clinical and commercial trade-offs
- Discuss how one-time curative interventions could disrupt current reimbursement models and challenge ROI metrics in dermatology
2:00 pm ️Panel Discussion: Searching for the ‘Crystal Ball of Dermatology’: Disease Modification
Synopsis
- What progress has the industry made in shifting from symptom management to truly modifying disease pathways in conditions like Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, and Pruritis?
- What are the key biological targets and mechanisms that show the most promise for delaying, slowing, or reversing disease progression in immunodermatology?
- What lessons can be learned from other therapeutic areas that have successfully developed disease-modifying treatments, and how can they be applied to dermatology?
- What impact would disease-modifying treatments have on the existing dermatology landscape?
2:45 pm Afternoon Networking Break
Addressing Unmet Need: Advancing Discovery, Development, and Patient Integration for Rare Disorders
3:15 pm Phase 3 Development of First-in-Class C5a Inhibitor Vilobelimab: Transforming Treatment for Pyoderma Gangrenosum
Synopsis
- Understand C5a inhibition how demonstrates a novel mechanism for targeting neutrophil-driven inflammation in PG
- Examine Phase 1 and 2a clinical data showcasing safety profile and biological proof of concept across multiple indications
- Discover the strategic approach to Phase 3 trial design that builds on demonstrated efficacy while addressing rare disease challenges
3:45 pm Epidermolysis Bullosa: Bridging Disease Complexity with Therapeutic Innovation
Synopsis
- Uncover the diverse genetic landscape of EB and how understanding molecular mechanisms can inform therapeutic strategies and target selection
- Navigate the unique challenges of rare disease patient recruitment, trial design, and addressing disease heterogeneity
- Examine emerging preclinical developments for EB and key considerations for translating these innovations to the clinic
4:15 pm Chair’s Closing Remarks & End of Conference Day One
4:20 pm Poster & Evening Networking Session
Synopsis
The learning and networking continues! This is the perfect opportunity to present your recent work, and spark discussions and potential future collaborations with fellow leaders looking to improve outcomes for patients with dermatological conditions!